Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins

Zhang,Bo; Zhan,Ge; Fang,Qing; Wang,Fang; Li,Yang; Zhang,Yuhao; Zhao,Lei; Zhang,Guocui; Li,Baoxin

doi:10.3892/mmr.2019.10692

Evaluation of cytochrome P450 3A4‑mediated drug‑drug interaction potential between P2Y12 inhibitors and statins

Authors:
- Bo Zhang
- Ge Zhan
- Qing Fang
- Fang Wang
- Yang Li
- Yuhao Zhang
- Lei Zhao
- Guocui Zhang
- Baoxin Li
View Affiliations

Affiliations: Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China
Published online on: September 19, 2019 https://doi.org/10.3892/mmr.2019.10692
Pages: 4713-4722

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ticagrelor and prasugrel are widely used in the treatment of acute coronary syndrome. The co‑administration of ticagrelor or prasugrel with statins in the clinic has already drawn a great deal of attention. The aims of the present study were to evaluate the safety and effectiveness, and guide the rational clinical use of, co‑administration of ticagrelor or prasugrel with statins by exploring potential drug interactions. The activity of cytochrome P450 family 3 subfamily A member 4 (CYP3A4) was detected, and its protein and mRNA expression levels were measured in a rat model and liver microsomes to evaluate the effect of the drug combinations on CYP3A4. High performance liquid chromatography, western blotting and reverse transcription‑quantitative PCR were used to perform these investigations. The in vitro experiments suggested that ticagrelor inhibited CYP3A4 activity, with IC50 and inhibitor constant (Ki) values of 68.74 and 26.47 µM, respectively; prasugrel also inhibited CYP3A4, activity with IC50 and Ki values of 16.24 and 10.84 µM, respectively. When different dosages of the antagonists were combined with simvastatin or atorvastatin, the metabolic rate was reduced more effectively at higher dosages when compared with lower dosages. An in vivo pharmacokinetic study demonstrated that the co‑administration of ticagrelor or prasugrel with simvastatin caused an increase in the principal pharmacokinetic parameters of the probe drug dapsone [area under the concentration/time curve (AUC)0‑t, AUC0‑∞ and t1/2] and a decrease in clearance compared with ticagrelor, prasugrel or simvastatin alone. Additional studies confirmed that the two investigated P2Y12 inhibitors were able to decrease the protein level of CYP3A4 by promoting protein degradation through the proteasomal pathway, and combination with statins such as simvastatin had a synergistic inhibitory effect on CYP3A4 activity. These results demonstrated that the co‑administration of P2Y12 inhibitors with simvastatin could markedly inhibit the activity of CYP3A4, and these findings will further influence the assessment of the clinical effectiveness (reduced or enhanced efficacy) and safety (bleeding and rhabdomyolysis) in the clinic.

View Figures

View References

1	Chen JJ, Zhang JX, Zhang XQ, Qi MJ, Shi MZ, Yang J, Zhang KZ, Guo C and Han YL: Effects of diosmetin on nine cytochrome P450 isoforms, UGTs and three drug transporters in vitro. Toxicol Appl Pharmacol. 334:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
2	Tang S, Chen A, Zhou X, Zeng L, Liu M and Wang X: Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 281:74–83. 2017. View Article : Google Scholar : PubMed/NCBI
3	Lin JH: CYP induction-mediated drug interactions: In vitro assessment and clinical implications. Pharm Res. 23:1089–1116. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lu J, Shao Y, Qin X, Liu D, Chen A, Li D, Liu M and Wang X: CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research. Sci Rep. 7:429222017. View Article : Google Scholar : PubMed/NCBI
5	Xie B, Lu YY, Luo ZH, Qu Z, Zheng CG, Huang XA, Zhou HY, Hu YJ and Shen XL: Tenacigenin B ester derivatives from Marsdenia tenacissima actively inhibited CYP3A4 and enhanced in vivo antitumor activity of paclitaxel. J Ethnopharmacol. 235:309–319. 2019. View Article : Google Scholar : PubMed/NCBI
6	Rendic S and Guengerich FP: Survey of human oxidoreductases and cytochrome P450 enzymes involved in the metabolism of xenobiotic and natural chemicals. Chem Res Toxicol. 28:38–42. 2015. View Article : Google Scholar : PubMed/NCBI
7	Wanwimolruk S and Prachayasittikul V: Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). EXCLI J. 13:347–391. 2014.PubMed/NCBI
8	Jin C, Kim MH, Bang J and Serebruany V: A prospective, randomized, open-label, blinded, endpoint study exploring platelet response to half-dose prasugrel and ticagrelor in patients with the acute coronary syndrome: HOPE-TAILOR study. Cardiology. 138:201–206. 2017. View Article : Google Scholar : PubMed/NCBI
9	Vyas A, Bash LD, Patel MD and Simpson RJ Jr: Changes in treatment patterns and incremental health care utilization due to P2Y12-associated complications in patients with acute coronary syndrome. J Manag Care Spec Pharm. 23:947–956. 2017.PubMed/NCBI
10	Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al: 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 130:2354–2394. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 32:2999–3054. 2011. View Article : Google Scholar : PubMed/NCBI
12	Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), ; Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, et al: ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 33:2569–2619. 2012. View Article : Google Scholar : PubMed/NCBI
13	Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 361:1045–1057. 2009. View Article : Google Scholar : PubMed/NCBI
14	Teng R, Mitchell PD and Butler KA: Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol. 69:477–487. 2013. View Article : Google Scholar : PubMed/NCBI
15	Zhou D, Andersson TB and Grimm SW: In vitro evaluation of potential drug-drug interactions with ticagrelor: Cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics. Drug Metab Dispos. 39:703–710. 2011. View Article : Google Scholar : PubMed/NCBI
16	Ancrenaz V, Deglon J, Samer C, Staub C, Dayer P, Daali Y and Desmeules J: Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 112:132–137. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ramasamy S, Kiew LV and Chung LY: Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 19:2588–2601. 2014. View Article : Google Scholar : PubMed/NCBI
18	Umemura K and Iwaki T: The pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy Japanese volunteers. Clin Pharmacol Drug Dev. 5:480–487. 2016. View Article : Google Scholar : PubMed/NCBI
19	Teng R, Hammarberg M, Carlson GF, Bokelund-Singh S, Ruderfelt T and Blychert E: Pharmacokinetic profiles of ticagrelor orodispersible tablets in healthy western and Japanese Subjects. Clin Drug Investig. 37:1035–1045. 2017. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Savarese G and Lund LH: Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue. Int J Cardiol. 249:77–78. 2017. View Article : Google Scholar : PubMed/NCBI
22	Lodola A: Developing combination drugs in preclinical studies. Methods Mol Biol. 691:3–16. 2011. View Article : Google Scholar : PubMed/NCBI
23	Zhi D, Feng PF, Sun JL, Guo F, Zhang R, Zhao X and Li BX: The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides. Eur J Pharm Sci. 76:149–155. 2015. View Article : Google Scholar : PubMed/NCBI
24	Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS and Winters KJ: Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 28:1483–1494. 2008. View Article : Google Scholar : PubMed/NCBI
25	Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M and McLeod HL: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 44:279–304. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT and Kliewer SA: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 102:1016–1023. 1998. View Article : Google Scholar : PubMed/NCBI
27	Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS and O'Donoghue ML: Concomitant administration of clopidogrel with statins or calcium-channel blockers: Insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). JACC Cardiovasc Interv. 6:1275–1281. 2013. View Article : Google Scholar : PubMed/NCBI
28	Holmberg MT, Tornio A, Hyvarinen H, Neuvonen M, Neuvonen PJ, Backman JT and Niemi M: Effect of grapefruit juice on the bioactivation of prasugrel. Br J Clin Pharmacol. 80:139–145. 2015. View Article : Google Scholar : PubMed/NCBI
29	Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX and Zhou Q: Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Ther Clin Risk Manag. 11:449–467. 2015.PubMed/NCBI
30	Ju A, Li YY, Qu Z and Li Q: Impact of the herbal breviscapine on the pharmacokinetics of simvastatin in rats: The involvement of CYP3A4. Drug Res (Stuttg). 67:271–274. 2017. View Article : Google Scholar : PubMed/NCBI
31	Shu N, Hu M, Ling Z, Liu P, Wang F, Xu P, Zhong Z, Sun B, Zhang M, Li F, et al: The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1. Sci Rep. 6:330722016. View Article : Google Scholar : PubMed/NCBI
32	Dinicolantonio JJ and Serebruany VL: Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology. 124:105–107. 2013. View Article : Google Scholar : PubMed/NCBI
33	Huan JY, Streicher JM, Bleyle LA and Koop DR: Proteasome-dependent degradation of cytochromes P450 2E1 and 2B1 expressed in tetracycline-regulated HeLa cells. Toxicol Appl Pharmacol. 199:332–343. 2004. View Article : Google Scholar : PubMed/NCBI
34	Liao M, Faouzi S, Karyakin A and Correia MA: Endoplasmic reticulum-associated degradation of cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: Further characterization of cellular participants and structural determinants. Mol Pharmacol. 69:1897–1904. 2006. View Article : Google Scholar : PubMed/NCBI
35	Feng PF, Zhao L, Guo F, Zhang B, Fang L, Zhan G, Xu X, Fang Q, Liang Z and Li B: The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact. 293:115–123. 2018. View Article : Google Scholar : PubMed/NCBI